News

"Our goal is to help MissionPoint members improve their health status," said Jason Dinger, CEO of MissionPoint Health Partners. "In our experience with managing the health of populations,

An official from WHO noted that the death rate due to this deadly disease has now increased to 70%. The death toll from the Ebola virus outbreak has

Vaxart’s founder and chief scientific officer, Sean Tucker, PhD, discussed the data in a presentation today at the 15th Annual World Vaccine Congress in Brussels. "A tablet vaccine

"We are very excited having selected PPD, one of the world’s leading contract research organizations, to be our strategic clinical development partner in advancing our assets through the

The audit will be conducted in two phases, both of which are expected to be completed by early November 2014. In the first phase, INC Research Quality and

Triumeq is a once-daily single-pill regimen, which combines the integrase strand transfer inhibitor (INSTI) dolutegravir with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. ViiV Healthcare Canada

Opdivo (nivolumab) is BMS’s investigational PD-1 immune checkpoint inhibitor, while Imbruvica (ibrutinib) is an oral Bruton’s tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The

Orexo anticipates a potential approval of the expanded label during the third quarter 2015. The application for initiation of treatment is supported by the data from the ISTART

Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types